##NMPA
LightNews LightNews
oncodaily.bsky.social
Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC

https://oncodaily.com/drugs/sacituzumab-193201

##AntibodyDrugConjugate ##Cancer ##ChinasNationalMedicalProductsAdministration ##NMPA ##OncoDaily ##Oncology ##Sacituzumab ##Tirumotecan
Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC - OncoDaily
Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC / antibody-drug conjugate, cancer, China's National Medical Products
oncodaily.com
December 3, 2024 at 9:01 AM
oncodaily.bsky.social
Dr. Reddy’s has launched Toripalimab in India: Advancing Treatment for Nasopharyngeal Carcinoma

https://oncodaily.com/insight/194236

##Cancer ##Cisplatin ##EMA ##Gemcitabine ##MHRA ##Nasopharyngeal ##Carcinoma ##NMPA ##OncoDaily ##Oncology ##ReddysLaboratories ##BiosciencesCo ##Toripalimab ##USFDA
Dr. Reddy’s has launched Toripalimab in India: Advancing Treatment for Nasopharyngeal Carcinoma - OncoDaily
Dr. Reddy’s has launched Toripalimab in India: Advancing Treatment for Nasopharyngeal Carcinoma / cancer, Cisplatin, EMA, Gemcitabine, M.V. Ramana, MHRA,
oncodaily.com
December 2, 2024 at 11:00 PM
seldon-dengyue.bsky.social
📢 Breaking News in Oncology!
The NMPA has conditionally approved #Zeprumetostat Tablets (#Airuijing) by Jiangsu Hengrui Pharmaceuticals.

#JiangsuHengrui #InnovationDrug #PeripheralTCellLymphoma #RrPTCL #RelapsedCancer #RefractoryCancer #EZH2Inhibitor #TargetedTherapy #NMPA
#HongKongDengYueMedicine
November 3, 2025 at 7:04 AM
ipharmaservices.bsky.social
#中国 - #NMPA は、従来の全身療法およびFGFR標的療法が不応となったFGFR2融合/再構成を有する進行・転移性#胆管癌 に対する新規クラス1治療薬を優先承認しました。
www.ipharmacenter.com/post/china-n...
#腫瘍学 #胆管癌 #精密医療
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresJuly 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatm...
www.ipharmacenter.com
August 13, 2026 at 4:42 AM
amyleefans.com
On this day in #Evanescence history, June 18, 2008, Amy Lee was honored with the prestigious Songwriter Icon Award by the National Music Publishers’ Association in New York City. 👑🎶

#AmyLee #Songwriter #RockIcons #OnThisDay #MusicHistory #NMPA #WomenInMusic
June 18, 2025 at 4:05 PM
dengyuemedicine.bsky.social
China NMPA Approves Donanemab Injection for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Donanemab #EliLilly #AlzheimersDisease #NMPA #DrugApproval #MonoclonalAntibody #Neuroscience #ChinaPharma
November 12, 2025 at 6:56 AM
dengyuemedicine.bsky.social
China NMPA Approves Funakizumab Injection for Moderate-to-Severe Plaque Psoriasis

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#NMPA #DrugApproval #MonoclonalAntibody #IL17A #Psoriasis #BiopharmaChina #InnovativeDrug
October 31, 2025 at 6:15 AM
ipharmaservices.bsky.social
#中国 - #NMPA 优先批准了一款全新的1类疗法，用于治疗既往经系统治疗和FGFR靶向治疗失败、且携带FGFR2融合/重排的晚期/转移性#胆管癌 患者。 www.ipharmacenter.com/post/china-n...
#肿瘤学 #胆管癌 #精准医疗
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresJuly 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatm...
www.ipharmacenter.com
August 13, 2026 at 4:41 AM
newsen.bsky.social
DualityBio Secures China NMPA Acceptance for Pivotal Cancer Therapy Application#China#Shanghai#DualityBio#NMPA#Trastuzumab_Pamirtecan
DualityBio Secures China NMPA Acceptance for Pivotal Cancer Therapy Application
DualityBio has received acceptance from China's NMPA for its biologics license application for trastuzumab pamirtecan, aiming to treat HER2-positive breast cancer. The application highlights promising trial results.
third-news.com
April 9, 2026 at 5:01 PM
newsen.bsky.social
Ascletis Pharma Finalizes Pre-NDA Consultation for Denifanstat in China#China#Hong_Kong#Ascletis#NMPA#Denifanstat
Ascletis Pharma Finalizes Pre-NDA Consultation for Denifanstat in China
Ascletis Pharma has successfully completed the pre-NDA consultation for denifanstat, a treatment for moderate-to-severe acne, with China's NMPA, paving way for its drug application.
third-news.com
October 14, 2025 at 10:04 AM
jyves94.bsky.social
⚡️ #CARsgen a soumis deux demandes d' #IND auprès de la #NMPA pour son produit #Allogénique ciblant #BCMA avec cellules #CAR_T 🧬, #CT0596
Les demandes visent à initier deux essais cliniques de phase Ib/II pour le #MyélomeMultiple R/R et de la #Leucémie #pPCL
www.prnewswire.com/news-release...
CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it...
www.prnewswire.com
December 29, 2025 at 5:22 AM
medchemexpress.bsky.social
T-DXd + #Pertuzumab advances first-line treatment for #HER2-positive metastatic #BreastCancer.
Approved by #NMPA and #FDA, this ADC-based combination showed:
🔹44% reduction in progression/death risk 🔹Median PFS: 40.7 months 🔹ORR: 85.1%.
Expanding the potential of ADCs in precision oncology.
August 12, 2026 at 12:01 PM
ipharmaservices.bsky.social
La #NMPA en #Chine a approuvé l'injection de #Rexobin (Shanghai Huatai Biological Pharmacy) en procédure prioritaire pour adultes (≥40kg) avec poussées de #psoriasis pustuleux généralisé
www.ipharmacenter.com/post/china-n...
#Dermatology #RareDiseases #Pharma #healthcare
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresThe NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatment is intend...
www.ipharmacenter.com
August 26, 2026 at 4:09 PM
ipharmaservices.bsky.social
La #NMPA de #China aprobó la inyección de #Rexobin (Shanghai Huatai Biological Pharmacy) por vía prioritaria para adultos (≥40kg) con brotes de #psoriasis pustulosa generalizada
www.ipharmacenter.com/post/china-n...
#Dermatology #RareDiseases #Pharma #healthcare
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresThe NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatment is intend...
www.ipharmacenter.com
August 26, 2026 at 4:09 PM
ipharmaservices.bsky.social
La #NMPA autorise l'injection Rexobin (Shanghai Huatai Bio / SHA: 600521) en procédure prioritaire contre les poussées de #psoriasis pustuleux généralisé chez l'adulte (≥40kg)
www.ipharmacenter.com/post/china-n...
#NMPA #Psoriasis #Dermatologie #Pharma
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresThe NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatment is intend...
www.ipharmacenter.com
August 26, 2026 at 1:57 PM
ipharmaservices.bsky.social
国家药监局优先审评批准上海华泰生物 的瑞索宾注射液，用于治疗成人泛发性脓疱型银屑病发作。
www.ipharmacenter.com/post/china-n...
#NMPA #银屑病 #罕见病 #新药批准
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresThe NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatment is intend...
www.ipharmacenter.com
August 26, 2026 at 1:57 PM
ipharmaservices.bsky.social
La #NMPA aprobó la inyección #Rexobin (Shanghai Huatai Bio) por vía prioritaria para brotes de #psoriasis pustulosa generalizada en adultos (≥40kg).

www.ipharmacenter.com/post/china-n...

#NMPA #Psoriasis #Dermatologia #EnfermedadesRaras
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresThe NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatment is intend...
www.ipharmacenter.com
August 26, 2026 at 1:56 PM
ipharmaservices.bsky.social
中国国家药品监督管理局（NMPA）已批准 fenzalotuzumab 联合来那度胺（lenalidomide）和地塞米松（dexamethasone），用于治疗既往接受过治疗的多发性骨髓瘤患者。
www.ipharmacenter.com/post/china-n...
#中国 #NMPA #多发性骨髓瘤 #医药
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresJuly 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatm...
www.ipharmacenter.com
August 18, 2026 at 6:12 PM
ipharmaservices.bsky.social
#China’s #NMPA approves #fenzalotuzumab injection with #lenalidomide and #dexamethasone for previously treated #multiplemyeloma
www.ipharmacenter.com/post/china-n...
#China #NMPA #Myeloma #Pharma
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresJuly 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatm...
www.ipharmacenter.com
August 18, 2026 at 6:11 PM
ipharmaservices.bsky.social
#China: #NMPA lässt Therapie für fortgeschrittenes #Cholangiokarzinom mit FGFR2-Fusionen nach Vortherapie zu. www.ipharmacenter.com/post/china-n...
#Onkologie #Präzisionsmedizin
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresJuly 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatm...
www.ipharmacenter.com
August 13, 2026 at 4:41 AM
ipharmaservices.bsky.social
#China: La #NMPA aprueba terapia para #colangiocarcinoma avanzado con fusions FGFR2 tras fracaso de tratamientos previos.
www.ipharmacenter.com/post/china-n...
#Oncología #MedicinaDePrecisión
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresJuly 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatm...
www.ipharmacenter.com
August 13, 2026 at 4:40 AM
ipharmaservices.bsky.social
#China - La #NMPA concede aprobación prioritaria a una nueva terapia de Clase 1 para tratar el #colangiocarcinoma avanzado/metastásico con fusiones/reordenamientos de FGFR2 en pacientes que han fracasado a terapias sistémicas y dirigidas a FGFR previas.
www.ipharmacenter.com/post/china-n...
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresJuly 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatm...
www.ipharmacenter.com
August 13, 2026 at 4:39 AM
ipharmaservices.bsky.social
#China - Die #NMPA hat die #Rexobin-Injektion (Shanghai Huatai Biological Pharmacy) für Erwachsene mit Schüben von generalisierter pustulöser #Psoriasis (#GPP) zugelassen. www.ipharmacenter.com/post/china-n...
#GPP #Dermatologie #Rexobin #Gesundheitstechnologie
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresJuly 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatm...
www.ipharmacenter.com
August 13, 2026 at 4:35 AM
ipharmaservices.bsky.social
#Chine - La #NMPA approuve l'injection de #Rexobin (Shanghai Huatai Biological Pharmacy) pour les adultes souffrant de poussées de #psoriasis pustuleux généralisé (#GPP).
www.ipharmacenter.com/post/china-n...
#GPP #Dermatologie #Rexobin #TechnologieDeLaSanté
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresJuly 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatm...
www.ipharmacenter.com
August 13, 2026 at 4:34 AM
ipharmaservices.bsky.social
#China - La #NMPA aprueba la inyección de #Rexobin (Shanghai Huatai Biological Pharmacy) para adultos con brotes de #psoriasis pustulosa generalizada (#GPP).
www.ipharmacenter.com/post/china-n...
#GPP #Dermatología #Rexobin #TecnologíaMédica
China: NMPA Approves New Therapies | 2026
Rexobin Approved for Pustular Psoriasis FlaresJuly 29, 2026 The NMPA has authorized Rexobin injection, submitted by Shanghai Huatai Biological Pharmacy, through the priority review pathway. The treatm...
www.ipharmacenter.com
August 13, 2026 at 4:34 AM